Induced pluripotent stem cell-derived mesenchymal stem cells for modeling and treating metabolic associated fatty liver disease and metabolic associated steatohepatitis:Challenges and opportunities  

作　　者：Bárbara Silva José Bragança 

机构地区：[1]Algarve Biomedical Center-Research Institute,University of Algarve,Faro 8005-139,Portugal [2]JoséBragança,Algarve Biomedical Center,University of Algarve,Faro 8005-139,Portugal [3]JoséBragança,Faculty of Medicine and Biomedical Sciences,University of Algarve,Faro 8005-139,Portugal [4]PhD Program in Biomedical Sciences,Faculty of Medicine and Biomedical Sciences,University of Algarve,Faro 8005-139,Portugal [5]Faculty of Medicine and Biomedical Sciences,Algarve Biomedical Center-Research Institute,University of Algarve,Faro 8005-139,Portugal [6]Champalimaud Research Program,Champalimaud Centre for the Unknown,Lisbon 1000-001,Portugal

出　　处：《World Journal of Stem Cells》2025年第2期17-28,共12页世界干细胞杂志(英文)

基　　金：American Heart Association Award,No.24IVPHA1288417;and FCT Fellowships,No.2022.13253.BDANA.

摘　　要：The potential of induced pluripotent stem cells(iPSCs)for modeling and treating metabolic associated fatty liver disease(MAFLD)and metabolic associated steatohepatitis(MASH)is emerging.MAFLD is a growing global health concern,currently with limited treatment options.While primary mesenchymal stem cells hold promise,iPSCs offer a versatile alternative due to their ability to differentiate into various cell types,including iPSC-derived mesenchymal stem cells.However,challenges remain,including optimizing differentiation protocols,ensuring cell safety,and addressing potential tumorigenicity risks.In addition,iPSCs offer the possibility to generate complex cellular models,including three-dimensional organoid models,which are closer representations of the human disease than animal models.Those models would also be valuable for drug discovery and personalized medicine approaches.Overall,iPSCs and their derivatives offer new perspectives for advancing MAFLD/MASH research and developing novel therapeutic strategies.Further research is needed to overcome current limitations and translate this potential into effective clinical applications.

关 键 词：Metabolic associated fatty liver disease Metabolic associated steatohepatitis Nonalcoholic fatty liver disease Nonalcoholic steatohepatitis Mesenchymal stem cells Induced pluripotent stem cells In vitro liver models 

分 类 号：R329.2[医药卫生—人体解剖和组织胚胎学]